tirzepatide phase 3 study results Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, trial Tirzepatide dose chart: complete dosing

It can also boost energy and metabolism, helping you burn fat

All documentation and evaluation of this compound remain confined to investigational, non-clinical laboratory research

It follows revelations that six cases of acute liver toxicity have been reported in Victoria in 2026, all linked to an unapproved peptide product labelled as Retatrutide

3,4 Further cytokine production can occur as the LL37/DNA complex can act as an auto-antigen by fitting into the groove of human leukocyte antigen-Cw6 that is then presented to the T-lymphocyte

Food and Drug Administration for the management of type 2 diabetes, weight management, and cardiovascular risk reduction